Cetera Investment Advisers
AZN icon

Cetera Investment Advisers’s AstraZeneca AZN Stock Holding History

Cetera Investment Advisers’s Portfolio AZN Stock Details AZN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-3,800
Closed -$10.1K – 5023
2026
Q1 		$10.1K Buy
+3,800
New +$733K ﹤0.01% 4694

Other funds holding AZN

EP
Evelyn Partners London $46.9B AUM
IA
Investor AB Stockholm, Sweden $14.4B AUM 4.07% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Legal & General Group
Legal & General Group London, United Kingdom $480B AUM 42.84% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Cetera Investment Advisers's AZN Position: Q2 2026 in Review

Cetera Investment Advisers increased its AstraZeneca (AZN) stake by 17% in Q2 2026, buying an estimated $7.23M and bringing the position to 261,104 shares worth $49.1M. The position accounts for 0.04% of the portfolio, ranked #417.

Cetera Investment Advisers first reported a position in AZN in Q3 2020 and has held it in 24 quarters since. 1,504 funds tracked by Wall St. Rank hold AZN as of Q2 2026.

  • Cetera Investment Advisers held 261,104 shares of AstraZeneca worth $49.1M as of Q2 2026.
  • Cetera Investment Advisers bought 38,447 AstraZeneca shares in Q2 2026, an estimated $7.23M.
  • AstraZeneca made up 0.04% of Cetera Investment Advisers's portfolio in Q2 2026, its #417 holding.
  • Cetera Investment Advisers first reported a position in AstraZeneca in Q3 2020 and has held it in 24 quarters since.
  • 1,504 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.

Based on Cetera Investment Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.